Diabetic retinopathy (DR) affects over 93 million people worldwide and is the number one cause of blindness among working age adults. These indicators coupled with the projected rise of patients diagnosed with diabetes, makes DR a serious and prevalent vision threating disease. Data from recent clinical trials demonstrate that in addition to the well accepted role of hyperglycemia, dyslipidemia is an important, but often overlooked factor in the development of DR. The central aim of this review article is to showcase the critical role of dyslipidemia in DR progression as well as highlight novel therapeutic solutions that take advantage of the vital roles lipid metabolism plays in DR progression.
Hammer, S. S., & Busik, J. V. (2017). The role of dyslipidemia in diabetic retinopathy. Vision Research, 139, 228–236. https://doi.org/10.1016/j.visres.2017.04.010